GEN Exclusives

More »

GEN News Highlights

More »
Jan 25, 2010

Dr. Reddy’s to Apply Aegis’ Intravail Delivery Technology to Marketed Therapeutics

  • Dr. Reddy’s Laboratories negotiated access to Aegis Therapeutics’ Intravail® drug-delivery technology for use with specific marketed therapeutics that currently represent annual worldwide sales of over $1 billion.

    Intravail comprises a broad class of chemically synthesized transmucosal absorption enhancement agents. Aegis claims the technology enables the noninvasive systemic delivery of peptide, protein, nucleotide, or other small/large molecule drugs that have been deliverable by injection only until now.

    The company also states it has proven the feasibility of using Intravail to deliver a broad range of therapeutics of up to 30,000 Daltons molecular weight. These include calcitonin, growth hormone, leptin, PTH, insulin, erythropoietin, PYY-3-36, GLP-1 related peptides, glucagon, antisense drugs, and low molecular weight heparins.

    Aegis’ drug-delivery technologies also include its ProTek® protein- and peptide-stabilization excipients and Aegis Hydrogels™, which have been developed as absorption-enhancing, self-assembling nonpolymeric hydrogels.

    In December 2009, the company signed a licensing agreement with Roche, giving the latter access to its ProTek technology. The deal covers the use of specific excipients as stabilizers in certain manufacturing processes and formulations of protein-based therapeutics.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »